SCHEMBL1507889

SCHEMBL1507889

CCCCN(Cc1ccc2cccc(NC(=O)OC(C)(C)C)c2n1)Cc1ccc2cccc(NC(=O)OC(C)(C)C)c2n1

nearest known ligand 0.40

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
TP53 P04637 2/20 0.40
POLB P06746 1/20 0.40
TMEM97 Q5BJF2 3/20 0.38
SIGMAR1 Q99720 3/20 0.38
PIM1 P11309 1/20 0.38
PIM2 Q9P1W9 1/20 0.38
CNR2 P34972 1/20 0.37
PLAU P00749 1/20 0.37
PDE10A Q9Y233 7/20 0.37
PDE4D Q08499 1/20 0.35
AKT1 P31749 1/20 0.35
MAPT P10636 1/20 0.35
ALOX15 P16050 1/20 0.35
KDM4E B2RXH2 1/20 0.35
KMT2A Q03164 1/20 0.35
L3MBTL1 Q9Y468 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1507701 0.90 PLAU (0.42) TP53PIM1PIM2PLAUPDE10A
SCHEMBL22765025 0.85 PLAU (0.41) TP53PIM1PIM2PLAUPDE10A
SCHEMBL1507749 0.82 TP53 (0.40) TP53POLBPIM1PIM2CNR2
SCHEMBL1507944 0.80 PLAU (0.43) TP53PIM1PIM2PLAUPDE10A
SCHEMBL7748081 0.75 MAPT (0.57) TP53POLBMAPTKMT2A
SCHEMBL30471577 0.75 MAPT (0.57) TP53POLBMAPTKMT2A
SCHEMBL5959295 0.75 PLAU (0.49) TP53PLAUMAPT
SCHEMBL14551175 0.72 PLAU (0.46) POLBPIM1PIM2PLAUMAPT
SCHEMBL22556188 0.71 TDP1 (0.61) TP53POLBMAPTKDM4EKMT2A
SCHEMBL1507925 0.71 MCHR1 (0.40) PDE10AMAPTALOX15

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8324196-B2 Polyquinoline derivatives and the therapeutic use thereof PALUMED S.A. (FR) 2012-12-04 US claimed
US-20120277265-A1 NOVEL POLYQUINOLINE DERIVATIVES AND THE THERAPEUTIC USE THEREOF CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (C.N.R.S.) (FR) 2012-11-01 US claimed
US-8247396-B2 Polyquinoline derivatives and therapeutic use thereof PALUMED S.A. (FR) 2012-08-21 US claimed
US-20090227626-A1 NOVEL POLYQUINOLINE DERIVATIVES AND THERAPEUTIC USE THEREOF PALUMED S.A. (FR) 2009-09-10 US claimed
US-8324196-B2 Polyquinoline derivatives and the therapeutic use thereof PALUMED S.A. (FR) 2012-12-04 US disclosed
US-20120277265-A1 NOVEL POLYQUINOLINE DERIVATIVES AND THE THERAPEUTIC USE THEREOF CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (C.N.R.S.) (FR) 2012-11-01 US disclosed
US-8247396-B2 Polyquinoline derivatives and therapeutic use thereof PALUMED S.A. (FR) 2012-08-21 US disclosed
EP-2289891-A2 Novel polyquinoline derivates and the therapeutic use thereof Palumed S.A. (FR) 2011-03-02 EP disclosed
US-20090227626-A1 NOVEL POLYQUINOLINE DERIVATIVES AND THERAPEUTIC USE THEREOF PALUMED S.A. (FR) 2009-09-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120277265-A1 NOVEL POLYQUINOLINE DERIVATIVES AND THE THERAPEUTIC USE THEREOF HTT, APP, PSEN1 TP53 2072/4885POLB 3368/4885TMEM97 733/4885
US-20090227626-A1 NOVEL POLYQUINOLINE DERIVATIVES AND THERAPEUTIC USE THEREOF HTT, UBQLN2, UBQLN1 TP53 3502/4885POLB 2526/4885TMEM97 1052/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.